

# **Lepu Medical Technology (Beijing) Co., Ltd.**

## **2023 Semi-annual Report**

## I. Important notice

The board of directors, supervisory board, directors, supervisors, and senior management of the company guarantee the authenticity, accuracy, and completeness of the content of the semi-annual report, without any false records, misleading statements, or major omissions, and shall bear individual and joint legal responsibilities.

The company leader Pu Zhongjie, the person in charge of accounting work Wang Yong, and the person in charge of accounting agency (accounting supervisor) Li Yun declare that they guarantee the authenticity, accuracy, and completeness of the financial report in this semi-annual report.

All directors have attended the board meeting to review this semi-annual report.

The company plans not to distribute cash dividends, issue bonus shares, or convert public reserve funds into share capital.

This Semi-annual Report has not been audited.

## II. Basic information of the Company

### 1. Company profile

Stock abbreviation	Lepu Medical	Stock code	300003
Stock exchange	Shenzhen Stock Exchange		
Contact person and information	Board Secretary		
Name	JIANG Weinan		
Tel.	010-80120622		
Office address	No. 37 Chaoqian Road, Changping District, Beijing		
E-mail	zqb@lepumedical.com		

### 2. Brief introduction to main businesses or products in the report period

The Company is a whole life-cycle solution provider in the field of cardiovascular diseases, and its business sectors are divided into medical devices, pharmaceutical, medical care solutions. The Company adheres to the medium-and long-term strategy of "innovation, consumption and internationalization" and is driven by multiple wheels to achieve long-term and steady business development. During the reporting period, the Company has realized an operating income of RMB 4301.4577 million, a net profit of RMB 961.4873 million attributable to shareholders of listed companies, a net profit of RMB 904.8747 million attributable to shareholders of listed companies after deducting non-recurring gains and losses, a net profit of RMB 975.1617 million attributable to

shareholders of listed companies after deducting expenses related to equity incentives implemented by the Company, and a net cash flow of RMB 141.7016 million from operating activities. At the end of the reporting period, the Company's total assets were RMB 24439.7632 million, and the net assets attributable to shareholders of listed companies were RMB 15721.4988 million, with a weighted average return on equity of 6.39%.

In terms of innovation, as shown in the following table, the innovative products of cardiovascular intervention will gradually realize commercialization, bring contribution income and profits to the Company, and drive performance growth.

**Important innovative products of vascular intervention are estimated by annual commercialization.**

	2023	2024	2025	2026
Coronary artery	★ Fractional Flow Reserve (FFR) measurement catheter	★ Pulsed sonic balloon	★ Rapamycin infusion system	★ Intra vascular ultrasound
	★ Disposable tubular stapler		Rapamycin-coated balloon	Drug-coated cutting balloon
	Coronary angiography fractional flow reserve (FFR) calculation software			Drug-coated coronary scoring balloon
				Pressure-controlled intermittent coronary sinus occlusion
Peripheral intervention	★ Small cutting balloon	Large cutting balloon	★ Vasodilator administration system	★ Bioabsorbable drug eluting stent
		★ Pulsed sonic balloon	★ Rapamycin drug-coated balloon	
		Above-the-knee PTA drug-coated balloon, below-the-knee PTA drug-coated balloon	Dissection Stent	
Structural heart disease	★ Biodegradable PFO occluder	Biodegradable ASD occluder	Transapical mitral valve clip repair system (chordae tendineae)	Biodegradable left atrial appendage occluder
		★ Transcatheter aortic valve replacement TAVR	★ Transapical mitral valve clip repair system	Transfemoral mitral valve clip repair system
CRM/electrophysiolog		★ Radiofrequency septal puncture needle and device	★ Cryo balloon ablation catheter and device	★ Ultrasonic ablation catheter and device for renal artery
			Smart pacemaker	★ Pulsed electric field ablation catheter and device
Heart failure			★ Implantable cardiac contractility modulator	★ Implantable resynchronization therapy pacemaker
				Left atrium assist device

Note: The above-mentioned important innovative products will contribute to the increase of operating incomes.

In terms of consumption, the Company continued to expand the sales channels of ophthalmology and dermatology products, and further promoted the research and development of new products as shown in the following table. For Ventura STD/Ventura STD HI-TECH orthokeratology lens independently developed by the Company, through technology integration and iteration, it can stably fit the cornea for the multi-zone gradual elevation design takes into account both the spherical aberration and the peripheral defocus, and has a good oxygen permeability and is comfortable to wear. During the reporting period, five medical beauty filling products (polylactic acid dermis injection filling agent, cross-linked sodium hyaluronate for injection, modified sodium pyruvate for injection, modified sodium complex for injection, and cross-linked sodium hyaluronate with poly-L-lactic acid) of the Company have been advanced to the clinical stage, and two ophthalmic products (orthokeratology lens, corneal breathable contact lens) have obtained license, five ophthalmic products (soft hydrophilic contact lens (daily contact lens), soft hydrophilic contact lens (monthly disposable), corneal breathable contact lens, multifunctional care solution for hard corneal contact lens and deproteinized solution for hard corneal contact lens) were registered, and three ophthalmic products (multifocal intraocular lens, orthokeratology lens and high-diopter corneal contact lens) have entered clinic stage.

Type	Name	Stage	Expected approval time
Ophthalmology Department	Orthokeratology lens (Ventura)	Approved	/
	Corneal breathable contact lens (Ventura)	Approved	/
	Soft hydrophilic contact lens (daily contact lens)	Registration	2023Q4
	Soft hydrophilic contact lens (monthly disposable)	Registration	2023Q4
	Corneal breathable contact lens (Xingtai)	Registration	2023Q4
	Multifunctional care solution for hard corneal contact lens	Registration	2024Q3
	Deproteinized solution	Registration	2024Q3
	Orthokeratology lens	Clinical	2024Q4
	High-diopter corneal contact lens	Clinical	2025Q4
	Multifocal intraocular lens	Clinical	2026Q3
Dermatology	Modified sodium pyruvate for injection	Clinical	2024Q4

	Polylactic acid dermis injection filling agent	Clinical	2025Q2
	Cross-linked sodium hyaluronate for injection	Clinical	2025Q3
	Modified sodium complex for injection	Clinical	2025Q3
	Cross-linked sodium hyaluronate with poly-l-lactic acid	Clinical	2026Q3
Orthodontics	U-shaped bite	Registration	2023Q3
	Standard orthodontic metal bracket	Type inspection	2024Q1
	Digital indirect bonding guide plate	Develop	2024Q1
	Muscle function corrector	Biological examination	2024Q1
	Double-layer TPU orthodontic device	Develop	2024Q2
	Double Layer TPU Membrane/Single Layer TPU Membrane	Develop	2024Q2

In terms of internationalization, the Company actively promoted overseas distribution, and gradually increased its sales share in overseas markets through flexible sales channels and diversified product portfolios. As of the disclosure date of the report, the Company has completed the local registration of 172 products in 47 countries, covering cardiovascular medical devices, ECG monitoring, orthopedics, surgery, in-vitro diagnosis and other products, among which 18 products have been certified by ANVISA in Brazil. At present, the Company has completed the registration of many countries along "the Belt and Road Initiatives", providing "admission tickets" for the overseas layout of products. Overseas registration of biodegradable VSD occluder (MemoSorb®), VSD occluder (oxide film) and other products is being actively promoted. In the future, the Company will continue to promote overseas clinical trials and registration of innovative products and practice the Company's internationalization strategies.

During the reporting period, the Company has participated in exhibitions in more than 20 countries of Dubai, Brazil, Turkey, the United States and Uzbekistan, etc., and established extensive sales networks in more than 160 countries and regions in Asia, Europe, North America and the Middle East, etc. The Company organized international academic conferences and exchanges on a number of cutting-edge innovative products, such as Ultrasonic Surgical System ultrasonic scalpel and MemoSorb® biodegradable occluder, etc., and the products were widely concerned and recognized by overseas doctors. The sales of minimally invasive surgical products

in Malaysia, India, Greece and other markets are growing steadily, and the Company is also continuing to promote the layout of such products in the Middle East, Brazil and South Korea, etc. The Company actively deploys overseas e-commerce platforms to expand the online overseas sales channels of household medical devices and consumer medical products. During the reporting period, the Company's products have been successfully launched in Lazada in Malaysia and Shopee independent website, and will be further promoted in other parts of Southeast Asia, and the Company continues to promote the launching of these products on the platforms of overseas e-commerce companies, such as TikTok and Tokopedia, etc.

During the reporting period, the construction of the production base of the Company's Malaysian branch continued to advance to enhance the Company's business development in Southeast Asia. The production base will be mainly used for overseas production of medical devices. The Company has initially completed the planning of land purchase, brand, qualification and operation system, and is promoting plant construction and qualification application, laying a solid foundation for radiating markets in Malaysia and surrounding countries and regions in Southeast Asia in the future.

### **(1) Medical devices**

The medical device sector is the largest income sector of our business, the segmented business segment includes cardiovascular intervention, in vitro diagnosis and surgical anesthesia, among which cardiovascular intervention is the core business sector of us. During the reporting period, the operating income of this segment reached RMB 2015.9500 million, of which the operating income of cardiovascular intervention innovative product portfolio increased by 13.27% year-on-year. Benefiting from the domestic substitution brought by the policy of volume-based procurement, the operating income of surgical anesthesia business increased by 21.16% year-on-year during the reporting period. As of the disclosing date, the Company has obtained 594 NMPA type II and type III licenses, 239 CE certificates and 33 FDA approvals in medical devices.

**Cardiovascular intervention:** The Company deeply develops innovative cardiovascular medical devices, with mature commercial products and extensive R&D lines in the fields of coronary artery and structural heart disease, and constantly promotes the research and development of products of peripheral blood vessels, cardiac rhythm management, electrophysiology, neuromodulation, heart failure and other fields.

In the field of coronary artery, as of the disclosure date of the report, the disposable radial artery compressor (WrisBand ®), disposable guiding sheath and coronary angiography fractional flow reserve (FFR) calculation software Vicor-Angio FFR have been successfully approved by NMPA. Coronary angiography fractional flow reserve (FFR) calculation software Vicor-Angio FFR is a fast, accurate and economical evaluation tool for coronary artery functionality (FFR) based on coronary angiography images to achieve accurate planning and full-process evaluation of PCI surgery. The successful approval of this product does not only enrich the product portfolio of Lepu Equipment in the field of interventional radiology, but also provide a new evaluation tool for realizing accurate coronary intervention therapy. The Company insists on independent innovation and continues to promote the research and development of new products. As of the disclosure date of the report, the products under research are progressing smoothly, and the pulsed sonic balloon, Percutaneous transluminal coronary angioplasty (PTCA) balloon dilatation and Coronary scoring balloon have submitted registration applications and are in the stage of information supplement; anchoring balloon is being registered; Clinical recruitment has been completed for rapamycin infusion system, and rapamycin infusion system is entered the stage of clinical follow-up.

Category	Product	Research and development	Preclinical	Clinical	Registration	Expected approval time
Functional balloon	☆ Pulsed sonic balloon	√	√	√	√	2024Q1
	Percutaneous transluminal coronary angioplasty (PTCA) balloon dilatation	√	√	√	√	2024Q1
	Coronary scoring balloon	√	√	√	√	2024Q1
	Anchoring balloon	√	√		√	2024Q3
	Drug-coated coronary scoring balloon	√				2026Q1
	Drug-coated cutting balloon	√				2026Q1
	Pressure-controlled intermittent coronary sinus occlusion	√				2026Q3
Drug-coated balloon	☆ Rapamycin infusion system	√	√	√		2025Q2
	Rapamycin coronary artery drug-coated balloon catheter	√	√	√		2025Q4
Intra vascular measurement	☆ Intravascular ultrasound (IVUS)	√				2025Q4
	Pressure sensor system	√				2025Q4

In the field of structural heart disease, Lepuxintai Medical Technology, a subsidiary, has a good overall development momentum and achieved a steady increase in revenue. Lepuxintai

Medical Technology has a total of 10 commercial congenital heart disease occluder products, among which the third generation MemoCarna® ASD occluder (oxide film) series products quickly became the backbone of the congenital heart disease occluder product business after being approved for marketing in 2020. After the fourth generation MemoSorb® biodegradable occluder system was approved for marketing in 2022, it also quickly realized commercialization and became the flagship product of the subsidiary in the field of congenital heart disease. Clinical trials have been completed for the fourth generation MemoSorb® biodegradable atrial septal defect occluder has completed, and the registration application has been submitted to National Medical Products Administration in the second quarter of 2023, and is expected to be approved by National Medical Products Administration and put on the market in the second quarter of 2024. MemoSorb® biodegradable patent foramen ovale occluder is in the registration stage and is expected to be approved by National Medical Products Administration in 2023. Bio-Lefort® biodegradable left atrial appendage occluder is under research, and pre-clinical type inspection and animal experiments have been successfully completed for this product as planned. At present, the product has officially entered the stage of multi-center clinical trial recruitment. The clinical trial recruitment and follow-up have been successfully completed for transcatheter aortic valve replacement TAVR as planned. It is planned to submit the registration application to National Medical Products Administration at the end of 2023. RF-Lance® radiofrequency puncture instrument and puncture needle have been submitted for registration application.

Category	Product	Research and development	Preclinical	Clinical	Registration	Expected approval time
Occluder	MemoSorb® biodegradable atrial septal defect occluder	√	√	√	√	2024Q3
	☆MemoSorb® biodegradable patent foramen ovale occluder	√	√	√	√	2023Q3
	☆MemoSorb® bioabsorbable patent foramen ovale occluder	√	√	√		2025Q2
	Bio-Lefort® biodegradable left atrial appendage occluder	√	√	√		2025Q3
Aortic valve	☆ScienCrown® transcatheter aortic valve replacement TAVR	√	√	√		2024Q4
	☆ScienMelon® transcatheter heart valve prosthesis with macromolecular valve leaflet	√	√			2029Q3
	Transcatheter aortic valve (balloon dilatation)	√	√			2028Q2

	ScienChute® transcatheter aortic valve stenosis treatment	√				2026Q4
	ScienChute® pulsed sonic generation equipment	√				2026Q4
Mitral valve	☆ MemoClip-A ® transapical mitral valve clip repair system (clip)	√	√	√		2025Q1
	MemoChord® transapical mitral valve clip repair system (chordae tendineae)	√	√	√		2025Q4
	MemoClip-F ® transapical mitral valve clip repair system	√	√			2026Q4
	Transcatheter mitral valve replacement	√	√			2029Q2
Tricuspid valve	MemoClamp ® transcatheter tricuspid valve repair system	√				2028Q3
	Transcatheter tricuspid valve replacement	√				2029Q3
Pulmonary valve	Transcatheter pulmonary valve replacement	√				2028Q4
Inter-atrial septal puncture product	☆ RF-Lance® radiofrequency puncture instrument	√	√	√	√	2024Q1
	☆ RF-Lance® disposable radiofrequency septal puncture needle	√	√	√	√	2024Q1
	Disposable septal puncture system	√	√	√	√	2024Q1

In other segmentations of cardiovascular, as of the disclosure date of the report, the peripheral pulsed sonic balloon has been submitted for registration; Above-the-knee PTA drug-coated balloon and below-the-knee PTA drug-coated balloon have completed clinical recruitment, which are in the stage of conclusion and follow-up respectively. Radiofrequency ultrasound ablation catheter and device for renal denervation, Cryo balloon ablation catheter and device for atrial fibrillation and implantable deep brain nerve stimulator are in the clinical recruitment stage.

Category	Product	Research and development	Preclinical	Clinical	Registration	Expected approval time
<b>Peripheral intervention</b>						
Stent	☆ Bioabsorbable drug eluting stent	√	√			2026Q4
	Peripheral vascular dissection stent	√	√	√		2025Q4
Drug-coated balloon	Above-the-knee PTA drug-coated balloon	√	√	√		2024Q2
	Below-the-knee PTA drug-coated balloon	√	√	√		2024Q2
	☆ Vasodilator administration system	√	√	√		2025Q4
	☆ Rapamycin peripheral drug-	√	√	√		2025Q4

	coated balloon					
	☆ Rapamycin infusion system	√				2028Q4
	Non-compliant PTA drug balloon catheter (AVF lesion)	√	√	√		2025Q1
Functional balloon	Large cutting balloon	√	√	√	√	2024Q3
	☆ Pulsed sonic balloon	√	√	√	√	2024Q3
Volume reduction	Thrombus aspiration device	√				2025Q2
	Water-powered thrombectomy device	√				2027Q1
	Peripheral plaque rotational atherectomy system	√	√			2026Q1
	Rapid thrombus aspiration catheter and device	√	√		√	2024Q3/ 2024Q1
<b>Electrophysiolog</b>						
Ultrasonic ablation catheter for pulmonary artery denervation	☆ Ultrasonic ablation catheter and device for pulmonary artery denervation	√	√	√		2026Q4
	Ultrasonic ablation catheter and device for pulmonary artery denervation	√				2027Q2
Radiofrequency ablation	Radiofrequency ablation catheter and device for renal denervation	√	√			2027Q2
	Radiofrequency ablation catheter and device for chronic obstructive pulmonary disease (COPD)	√				2027Q2
	Radiofrequency venous cavity closing catheter and device	√	√	√		2024Q4
Pulsed electric field ablation	☆ Pulsed electric field ablation catheter and device for atrial fibrillation	√				2026Q2
Cryoablation	☆Cryo balloon ablation catheter and device	√	√	√		2025Q4
	Spray cryocatheter	√				2028Q2

	for chronic obstructive pulmonary disease (COPD)					
	Transbronchoscopic intracavitary cryocatheter	√				2026Q2
<b>Cardiac rhythm management products</b>						
Cardiac rhythm management products	Qinming8632 smart pacemaker	√	√	√		2024Q4
	MRI compatible smart pacemaker	√	√			2025Q2
	Implantable cardiac resynchronization defibrillator	√				2027Q4
<b>Neuro-modulation</b>						
Neuro-modulation	Implantable deep brain nerve stimulator	√	√	√		2025Q4
	Implantable vagus nerve stimulator	√				2026Q4
	Implantable spinal nerve stimulator	√				2027Q2
<b>Heart failure</b>						
Interatrial shunt device	Interatrial shunt device II (biodegradable)	√	√			2027Q1
	FireyDeva® interatrial shunt device III (radiofrequency ablation)	√	√			2025Q2
Circular mechanical support	Transcatheter left ventricular assist device	√	√			2026Q4
	Expandable left ventricular assist device	√				2027Q2
	Coronary artery protection and assist device	√				2027Q2
Others	☆ Implantable resynchronization therapy pacemaker	√				2026Q4
	☆ Implantable cardiac contractility modulator	√	√	√		2025Q4

**In vitro diagnosis:** The Company has a complete product line of in-vitro diagnosis business, covering biochemistry, immune (chemiluminescence), molecular, blood and coagulation, POCT and other in-vitro diagnosis segmentations and important technical platforms. Based on the

product characteristics and market demand, the Company launched four solutions of medical institutions, home health, pet medical care and high-end medical care, so as to realize the good development of routine business. During the reporting period, the Company's liver function biochemical reagent products participated in the bidding for centralized purchasing in Jiangxi in 2022, all products won the bid, and implementation will start on Jul. 1, 2023. The Company's coagulation reagent products have completed the declaration of bargaining purchase of inspection reagents in the Central Alliance of Xinjiang Uygur Autonomous Region in 2023, some products have successfully won the bid for Anhui centralized procurement project in 2022, and implementation will start on Jul. 1, 2023. All kinds of instruments and equipment, mainly automatic enzyme-free workstation and automatic blood type analyzer, have won more than 70 bidding projects.

**Surgical anesthesia:** Changzhou Bingkun's business focuses on surgical medical devices and auxiliary anesthesia care devices. The main products include surgical medical devices, such as staplers and ultrasonic scalpel, etc., as well as various auxiliary anesthesia care medical devices of central venous catheter kits and invasive medical blood pressure sensors. Changzhou Bingkun has an independent and complete business system integrating research and development, production and sales in related fields. Bingkun adjusted the marketing ideas in time, and won the bid with multi-brand and multi-products in volume-based procurement of different provincial alliances. The commercialization advantage brought by the implementation of volume-based procurement policy is more obvious, and the market share of stapler products is expected to be further improved. The electric endoscopic stapler covers quickly and has now entered hundreds of medical institutions. At the same time, Bingkun also actively explores the innovative scene application of absorbable material technology, biomaterial technology, medicine-machinery combination technology and energy-driven technology in the field of minimally invasive surgery and auxiliary anesthesia nursing, promoting the platform technology to take root in the subdivision field. During the reporting period, the absorbable material tissue clip has entered the clinical stage, and the clinical group has been successfully recruited.

## (2) **Pharmaceutical**

We are one of the platform companies for cardiovascular disease management in China, and our products mainly include active pharmaceutical ingredients and preparations. During the

reporting period, the pharmaceutical sector realized an operating income of RMB 1599.1206 million, including RMB 1404.3100 million for preparations (generic drugs) and RMB 194.8107 million for active pharmaceutical ingredients. As of the disclosure date of the report, the Company's sitagliptin phosphate tablets, empagliflozin tablets, doxazosin mesylate extended release tablets and rosuvastatin calcium tablets have been approved for marketing. In the future, the Company's pharmaceutical sector will continue to add new products, and select regional superior product categories for accurate delivery in accordance with local actual conditions.

The Company actively pays attention to the development direction of innovative drugs in cardiovascular field, and has reached a milestone agreement with Shanghai Minwei Biotechnology Co., Ltd. (hereinafter referred to as "Minwei Biotechnology") on the cooperation in research and development of innovative drugs. The Company focuses on endocrine, metabolic diseases and their complications, cardiovascular and other fields, and independently develops LAGMA platform and RAF™ ultra-long-acting molecular development platform to screen multifunctional macromolecules, prolong the drug half-life of macromolecules, reduce the frequency of drug use and improve patient compliance. During the reporting period, the GLP-1/GCGR/GIP-Fc fusion protein MWN101 independently developed by the Company obtained the implied clinical license from National Medical Products Administration Center for Drug Evaluation (CDE), and the approved indication was intended for the treatment of type 2 diabetes and obesity. This product is the first GLP-1/GCG/GIP-Fc fusion protein in China.

As of the disclosure date of the report, the CDE technical review of insulin glargine raw material and injection has been completed, and the review inspection by the Chinese Academy of Inspection has been completed. The review report has been sent to the company and CDE, and all inspection items are qualified.

Dulagopeptide injection biological analog drug is undergoing phase III clinical research, which will be mainly used for type II diabetes patients in the future to meet the treatment needs of patients who only need to reduce blood sugar but not lose weight;

The pilot production validation of smeglutide biological analog has been completed, and it is expected to apply for IND in the first quarter of next year for the treatment of diabetes and obesity patients.

### **(3) Medical care solutions**

The medical service and health management sectors are new business sectors actively cultivated by the Company. In the reporting period, the medical service and health management sector realized an operating income of RMB 686.3871 million, with a year-on-year increase of 15.23%. We provide medical service and health management for cardiovascular diseases through cardiovascular specialist hospitals, medical diagnostic laboratories and medical equipment e-commerce platforms. In terms of health management, based on the Lepu cloud platform, the Company focuses on three major services of medical-grade cardiac monitoring, home health monitoring and intelligent rehabilitation nursing, and provides various vital signs monitoring products and services for hospitals and individual consumers at all levels. The ECG detection products rely on artificial intelligence AI-ECG Platform, providing long-distance dynamic ECG monitoring services remotely.

The Company attaches great importance to the application of artificial intelligence in the medical field. Combined with the existing business and clinical needs, the Company focuses on the research and development of artificial intelligence medical applications, focusing on the three major fields of life indication monitoring of chronic patients, blood biomarker detection, and medical imaging applications related to cardiovascular intervention. As of the disclosure date of the report, the AI CGM (implantable) developed in accordance with artificial intelligence algorithm has been clinically recruited, registration application has been submitted for the multi-parameter noninvasive blood glucose meter NeoGIU® AI, and the artificial intelligence cardiac ultrasound assistant software (intelligent ultrasound information system) is in the clinical stage.

### 3. Major accounting data and financial index

Does the Company need to retrospectively adjust or restate previous annual accounting data?

Yes  No

	This reporting period	Same period of last year	Increase or decrease in this reporting period over the same period of last year
Operating revenue (RMB)	4,301,457,705.65	5,333,506,938.54	-19.35%
Net profits attributable to shareholders of the listed company (RMB)	961,487,273.99	1,268,027,645.71	-24.17%
Net profits attributable to shareholders of the Company after deducting non-recurring profits and losses (RMB)	904,874,709.56	1,263,510,359.96	-28.38%
Net cash flow generated from operating activities	141,701,593.18	1,178,292,977.74	-87.97%

(RMB)			
Basic revenues per share (RMB/share)	0.5163	0.7117	-27.46%
Diluted earnings per share (RMB/share)	0.5147	0.7039	-26.88%
Weighted average return on equity	6.39%	10.69%	-4.30%
	End of this report	End of last year	Increase or decrease at the end of this reporting period compared with the end of last year
Total assets (RMB)	24,439,763,235.06	24,484,033,145.01	-0.18%
Net assets attributable to shareholders of the listed company (RMB)	15,721,498,816.83	15,146,202,761.30	3.80%

Note: Excluding the expenses related to the equity incentive that the company has implemented, the net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses in the reporting period was RMB 975.1617 million, compared with RMB 1294.1031 million in the same period of the previous year, a year-on-year decrease of 24.65%.

#### 4. Number of shareholders and shareholding situation of the Company

Unit: Type of equity

Total number of ordinary shareholders at the end of the reporting period		77,895	The sum of preferred stock shareholders recovering voting rights at the end of reporting period (if any)	0	Total number of shareholders holding special voting shares (if any)	0
Shareholding of the top 10 shareholders						
Name of shareholder	Nature of shareholder	Shareholding ratio	Number of shares held	Number of shares held with restricted conditions	Pledge, marking or freezing information	
					Stock status	Quantity
725th Research Institute of China State Shipbuilding Corporation Limited	State-owned legal person	12.98%	244,063,788			
PU Zhongjie	Domestic natural person	12.13%	228,074,749	171,056,062	Pledge	158,140,000
WP MEDICAL TECHNOLOGIES,	Foreign legal person	6.59%	123,968,600	92,976,450		

INC	n					
Hong Kong Securities Clearing Company Limited	Foreign legal person	5.86%	110,242,800			
Houde Yimin (Beijing) Investment Management Co., Ltd.	Domestic non-state-owned legal person	3.60%	67,750,000		Pledge	23,634,454
Houde Yimin (Ningbo) Investment Management Co., Ltd.	Domestic non-state-owned legal person	1.91%	35,850,000			
Bank of China Limited - Huabao CSI medical trading open-end index securities investment fund	Others	1.79%	33,635,019			
China Construction Bank Corporation - mixed securities investment fund for China-Europe pension industry	Others	1.53%	28,745,349			
Industrial and Commercial Bank of China Limited - ETF trading open-end index securities investment	Others	0.82%	15,511,149			

fund						
China CITIC Bank Co., Ltd. - mixed securities investment fund for China-Europe Ruijian	Others	0.71%	13,357,382			
Description of associated relationships or concerted action of the above shareholders	Shareholders Mr. PU Zhongjie, WP Medical Technologies, Inc., Houde Yimin (Beijing) Investment Management Co., Ltd. and Houde Yimin (Ningbo) Investment Management Co., Ltd. were persons acting in concert within the meaning of PRC law. There is no relationship between other shareholders of the Company or concerted action as stipulated in Measures for the Administration of Acquisition of Listed Companies (Order No.35 of China Securities Regulatory Commission).					
Instruction to top 10 ordinary share shareholders participating in financing and securities business (if any)	None					

Does the Company have voting rights difference arrangement?

Yes No

## 5. Change of controlling shareholders or actual controllers

Change of the controlling shareholders within the reporting period

Applicable Not Applicable

There is no change in the controlling shareholders during the reporting period.

Change in actual controllers within the reporting period

Applicable Not Applicable

No change in actual controllers of the Company in the reporting period

## 6. Table of total number of company's preferred shareholders and shareholdings of top 10 preferred shareholders

There is not details about statement of shareholding informations of preferred shareholders in the reporting period of the Company.

## 7. Bonds existing on approval date of the annual report

Applicable  Not applicable

### (1) Basic bond information

Name of bonds	Abbreviation of bonds	Bond code	Issuance date	Maturity date	Amount of bonds (RMB 0,000)	Interest rate

Phase I Medium Term Note of Lepu Medical Technology (Beijing) Co., Ltd. in 2020	20 Lepu MTN001	102000638	Apr. 9, 2020	Apr. 13, 2023	600,000,000	0.0415
Phase II Medium Term Note of Lepu Medical Technology (Beijing) Co., Ltd. in 2020	20 Lepu MTN002	102001717	Sept. 1, 2020	Sept. 3, 2023	600,000,000	0.047

**(2) Financial index to the end of the reporting period**

Unit: RMB 0,000

Item	End of this report	End of previous year
Asset-liability ratio		
Item	This reporting period	Same period of last year
EBITDA interest coverage ratio		

**III Environmental and Social Responsibility**

Whether the listed company and its subsidiaries are affiliated to key pollution discharge units published by the Ministry of Environmental Protection

Yes No

**Environmental protection related policies and industry standards****(1) Wastewater discharge standard**

*Integrated Wastewater Discharge Standard GB8978-1996, Integrated Discharge Standard of Water Pollutants DB11/ 307-2013, Technical Specifications for Wastewater Monitoring HJ 91.1-2019, Technical Specification for Installation of Wastewater On-line Monitoring System (CODCr, NH3-N Et Al.) HJ 353-2019, Indirect Discharge for Emission Limitation of Nitrogen and Phosphorus for Industrial Waste Water DB 33/ 887-2013, Wastewater Quality Standards for Discharge To Municipal Sewers (CJ343-2010), Discharge Standard of Pollutants for Municipal Wastewater Treatment Plant GB 18918-2002, Discharge Standards of Water Pollutants for Pharmaceutical Industry Chemical Synthesis Products Category GB 21904-2008 and Discharge Standards of Water Pollutants for Pharmaceutical Industry Mixing/compounding and Formulation Category GB21908-2008.*

**(2) Waste gas discharge standard**

Emission Standard of Air Pollutants for Pharmaceutical Industry DB33/310005-2021, Emission Standard of Air Pollutants for Pharmaceutical Industry GB37823-2019, Emission Standard of Air Pollutants for Boiler GB13271-2014, Emission Standard of Air Pollutants for Boiler DB11/139—2015, Self-monitoring Technology Guideline for Pollution Sources HJ 819-2017, Integrated Emission Standard of Air Pollutants (DB11/501-2017)

(3) Noise emission standards:

Class 3 standards of Emission Standard of Industrial Enterprises Noise at Boundary GB12348-2008

(4) Solid waste

Standard for Pollution Control on Storage and Disposal Site of General Industrial Solid Wastes GB18599-2001/XG1-2013, Standard for Pollution Control on Hazardous Waste Storage GB18597-2001/XG1-2013, Technical Specification for Setting Identification Signs of Hazardous Waste HG1276-2022

(5) Others

Regulations on the Administration of Pollutant Discharge Permits, Measures for the Administration of Pollutant Discharge Permits, Environmental Access Guidance of Pharmaceutical Industry in Taizhou

Administrative permit for environmental protection

1. Lepu Pharmaceuticals Co., Ltd. (West Plant): The license was issued on April 19, 2023, valid for 5 years

Lepu Pharmaceuticals Co., Ltd. (East Plant): The license was issued on May 25, 2023, valid for 5 years

Lepu Pharmaceutical Technology Co., Ltd.: The license was issued on May 25, 2023, valid for 5 years

2. Zhejiang Lepu Pharmaceuticals Co., Ltd.: The license was issued on September 22, 2022, valid for 5 years

3. Lepu Pharmaceuticals (Beijing) Co., Ltd.: The license was issued on August 13, 2021, valid for 5 years

### **Treatment of pollutants**

1. Lepu Pharmaceuticals Co., Ltd

(1) Construction and operation of wastewater treatment facilities:

The existing sewage treatment station of Lepu Pharmaceuticals Co., Ltd. has a treatment capacity of 100t/d. After wastewater treatment, it is discharged into Xiangcheng Municipal sewage

treatment plant through the urban sewage network. Currently, the sewage treatment facility in the plant runs normally, and the treatment effect can meet the receiving standards of the urban sewage treatment plant of the city. The new sewage treatment facility is currently undergoing commissioning, and the identification of the hazardous waste storage warehouse in the plant has been updated in accordance with the requirements of the national technical specification for identification and labeling of hazardous waste. A new 100t/d sewage treatment facility is established and completed Lepu Pharmaceutical Technology Co., Ltd. and is currently being debugged.

(2) Construction and operation of waste gas treatment facilities:

All the pollutants in the boiler exhaust gas are in conformity with the standard for discharge, the exhaust gas treatment facilities operate normally, and the VOC and dust are in compliance with the standard for discharge after detection.

2. Zhejiang Lepu Pharmaceuticals Co., Ltd.:

(1) The current wastewater treatment station of Zhejiang Lepu Pharmaceutical has a treatment capacity of 1200t/d. After treatment, the wastewater uniformly enters Jiaojiang Municipal Sewage Treatment Plant, with good COD and total nitrogen removal effect in terms of wastewater treatment, and can ensure that the effluent meets the management standard of subsequent sewage treatment plant.

(2) Construction and operation of wastewater treatment facilities:

The Company has established a whole-plant waste gas collection and treatment system: In a single production workshop, the waste gas exhaust pipe of the production equipment is connected to the main exhaust pipe (negative pressure); The part that is easy to produce the waste gas without organization discharge is arranged on the upper part of the collecting hood, and connected to the exhaust gas discharge main. The Company also takes different treatment measures according to the characteristics of the waste gas discharged by the production process of different products. All kinds of organic solvent waste gas, film in use, resin, activated carbon, secondary condensation, primary water spray absorption are discharged into the exhaust gas main. The waste water treatment station shall be covered and treated with negative pressure air extraction. After pretreatment, it shall be put into the main pipe for RTO incineration. After biological deodorization, it shall be discharged to the standard.

3. Lepu Pharmaceuticals (Beijing) Co., Ltd.:

(1) Construction and operation of wastewater treatment facilities:

The existing sewage treatment station of Lepu Pharmaceutical (Beijing) Co., Ltd. has a treatment capacity of 40t/d, and the plant area is watered after wastewater treatment for greening

(not connected to the municipal pipe network). The sewage treatment facilities are in normal operation, and the treatment effect can meet the standards in table "Standard for Water Pollutant Discharge" DB11/307-2013b under normal circumstances. However, because the sewage source water is composed of production sewage, domestic sewage and laboratory wastewater, the source water is unstable with too low limit value, so occasionally a certain data exceeds the standard. In October 2022, sewage online monitoring equipment was installed and networked with the Beijing Municipal Bureau of Ecology, and the four main indicators of sewage (COD, ammonia nitrogen, flow and PH) could be received in real time. In the first half of 2023, the operation was generally stable, but due to the assessment of transmission rate, marking and efficiency by the Beijing Municipal Bureau of Ecology, and additionally, there are occasionally exceeded standards plus secondary measurement of reprocessing flowmeter for reflux after exceeding standards and other problems, it is interviewed and supervised by the Changping District Ecology Bureau for many times, without administrative punishment, and it has not been interviewed or supervised since late May.

After the application for an emission permit in March 2023, the emission law has been changed from continuous emission to intermittent emission, and after the approval of mid-April, the problem of effective low and substandard will be solved.

In May 2023, logistics personnel were organized to transform sewage pipes in order to solve the problem of secondary measurement of flowmeters.

In June 2023, a 4-parameter water quality analyzer is purchased to analyze and test the main parameters of sewage water quality internally. When anomalies are found, the reflux treatment valve can be opened in advance, and the sewage can be discharged after the water quality is qualified to avoid exceeding the standard to the maximum extent.

#### (2) Construction and operation of waste gas treatment facilities:

All the pollutants in the boiler exhaust gas are discharged according to the standard, the exhaust gas treatment facilities are in normal operation, and the dust is discharged according to the standard.

### **Environmental self-monitoring program**

#### 1. Lepu Pharmaceuticals Co., Ltd

The Company formulates a self-monitoring plan according to the requirements of the government environmental protection department and the discharge permit implementation standards and entrusts a qualified third-party monitoring company to carry out monitoring in order to improve the Company's environmental management, master the Company's emission of various pollutants, evaluate the Company's impact on the surrounding environment, strengthen the

Company's emission management of pollutants in the production process, accept the supervision and inspection of the environmental protection department.

(1) Monitoring project

Wastewater monitoring items: Flow rate, pH value, chemical oxygen demand, ammonia nitrogen, total phosphorus, total nitrogen, suspended matter, five-day BOD, acute toxicity, total organic carbon;

Waste gas monitoring items: Nitrogen oxides, particulate matter, sulfur dioxide, non-methane hydrocarbons, Ringelmann blackness;

Noise monitoring items: Noise of the plant at boundary;

Surrounding environment quality monitoring item: Non-methane hydrocarbon, odor concentration, hydrogen sulfide, ammonia, particulate matter.

(2) Monitoring frequency

Frequency of wastewater monitoring: Flow rate, pH value, chemical oxygen demand, ammonia nitrogen, total phosphorus, total nitrogen, suspended matter, five-day BOD for once every month, once half a year for acute toxicity and total organic carbon;

Organized waste gas monitoring: Nitrogen oxides once a month, once half a year for non-methane hydrocarbon, sulfur dioxide, Ringelmann blackness and particulate matter;

Frequency of monitoring around unorganized waste gas plant boundary: Non-methane hydrocarbon, odor concentration, hydrogen sulfide, ammonia, particulate matter for once half a year.

2. Zhejiang Lepu Pharmaceuticals Co., Ltd.:

The environmental self-monitoring plan is developed in 2019 according to the requirements of the superior department and the company in order to improve the Company's environmental management, grasp the Company's emission of various pollutants, evaluate the Company's impact on the surrounding environment, strengthen the Company's emission management of pollutants in the production process, accept the supervision and inspection of the environmental protection department, and provide a reference basis for the pollution prevention and control of the enterprise.

(1) Monitoring project

Wastewater monitoring items: COD, NH<sub>3</sub>-N, PH, SS, BOD, petroleum, toluene, total phosphorus, total nitrogen, sulfide.

Waste gas monitoring items: SO<sub>2</sub>, NO<sub>X</sub>, non-methane hydrocarbon, toluene, ethanol, methanol, dichloromethane, tetrahydrofuran, odor concentration, dioxins.

Noise monitoring items: Noise of the plant at boundary;

Surrounding environment quality monitoring item: Non-methane hydrocarbon, ammonia, hydrogen chloride, odor concentration.

(2) Monitoring frequency

The main waste water outlet is automatically monitored continuously throughout the day.

Manual monitoring COD, NH<sub>3</sub>-N once every day, and once every month for PH, SS, BOD, petroleum, toluene, total phosphorus, total nitrogen, sulfide.

Exhaust gas: SO<sub>2</sub>, NO<sub>x</sub>, non-methane hydrocarbon once a month, once every two months for toluene, ethanol, methanol, dichloromethane, tetrahydrofuran, odor concentration, once a year for dioxins.

Noise and surrounding environmental quality are monitored once every six months, and groundwater and soil are fully indexed once half a year.

3. Lepu Pharmaceuticals (Beijing) Co., Ltd.:

The Company formulates a self-monitoring plan according to the requirements of the government environmental protection department and the discharge permit implementation standards and entrusts a qualified third-party monitoring company to carry out monitoring in order to improve the Company's environmental management, master the Company's emission of various pollutants, evaluate the Company's impact on the surrounding environment, strengthen the Company's emission management of pollutants in the production process, accept the supervision and inspection of the environmental protection department.

(1) Monitoring project

Wastewater monitoring items: pH value, chemical oxygen demand, ammonia nitrogen, total phosphorus, total nitrogen, suspended matter, five-day BOD, acute toxicity, total organic carbon;

Waste gas monitoring items: Nitrogen oxides, particulate matter, sulfur dioxide, non-methane hydrocarbons, Ringelmann blackness;

Noise monitoring items: Noise of the plant at boundary;

Surrounding environment quality monitoring item: Non-methane hydrocarbon, odor concentration, hydrogen sulfide, ammonia, particulate matter.

(2) Monitoring frequency

Frequency of wastewater monitoring: pH value, COD, ammonia nitrogen, total phosphorus, total nitrogen, suspended matter, five-day BOD once a month, and acute toxicity, total organic carbon permits are required to be semiannual, and now changed to be quarterly due to the report of environmental tax;

Organized waste gas monitoring: Nitrogen oxides once a month in the heating season, once half a year for non-methane hydrocarbon, sulfur dioxide, Ringelmann blackness and particulate matter;

Frequency of monitoring around unorganized waste gas plant boundary: Non-methane hydrocarbon, odor concentration, hydrogen sulfide, ammonia, particulate matter for once half a year.

### **Emergency plan for environmental emergencies**

In order to prevent and reduce the occurrence of environmental emergencies, control, mitigate and eliminate the hazards caused by environmental emergencies, establish and improve the emergency mechanism of environmental emergencies, improve the ability of the enterprise to deal with environmental emergencies, and effectively prevent, timely control and eliminate all kinds of environmental emergencies, the Company shall take the following measures:

#### 1. Composition of headquarters

##### (v) Emergency response

##### ① Alarm and communication

##### ② On-site rescue

##### (3) Emergency rescue of environmental pollution accidents

##### ① Pollutants and main sources

##### ② Cause analysis of environmental pollution

##### ③ Emergency rescue measures for environmental pollution accidents

##### ④ Disposal of environmental pollution accidents and preventive measures

##### (4) Assurance measures

##### ① Material supply guarantee

##### ② System guarantee

##### (5) Training and drilling

### **Conditions related to the investment in environmental governance and protection and payment of environmental protection tax**

In the first half of 2023, Lepu Pharmaceuticals Co., Ltd. invested RMB 2,160,000 in environmental governance and protection, and paid RMB 7854.33 of environmental protection tax.

In the first half of 2023, Lepu Pharmaceuticals Co., Ltd. invested RMB 12,310,000 in environmental governance and protection, and paid RMB 1503.31 of environmental protection tax.

In the first half of 2023, Lepu Pharmaceuticals (Beijing) Co., Ltd., has its total investment in environmental governance and protection of 121796.33, of which: Online monitoring operation and maintenance of RMB 35,000, sewage agents of RMB 27,000, environmental tax of RMB 4367.79 from January to June, water resources tax of RMB 42553.54, sewage testing fee of RMB 11,875.

## Administrative penalties for environmental problems during the reporting period

Name of the Company or subsidiary	Cause of punishment	Violation situation	Penalty result	The impact on the production and operation of listed companies	Corrective action of the Company
Lepu Pharmaceuticals Co., Ltd	None				
Zhejiang Lepu Pharmaceuticals Co., Ltd.:	None				
Lepu Pharmaceuticals (Beijing) Co., Ltd.:	Not implemented in accordance with the requirements of the Measures for the Administration of Pollutant Discharge Permits (Trial)	Beijing Lepu Pharmaceuticals belongs to the key management unit of pollutant discharge permit. The master discharge port of DW001 wastewater should carry out manual monitoring of total phosphorus, five-day BOD, total nitrogen and suspended matter once a month as required, and manual monitoring of acute toxicity and total organic carbon once a quarter. The total number of monitoring should be completed 56 times a year. From March 1, 2021, the implementation of the Regulations on the Administration of Pollutant Discharge Permits to December, the total number of monitoring times was missing 23 times, and the missing rate of monitoring indicators was 41.1%.	A fine of RMB 65,000 is imposed	None	Internal notification and criticism of relevant staff, and internal training of environmental protection testing work. Following testing will be carried out in strict accordance with relevant management regulations.

## IV. Financial statements

The unit of the statements in the financial notes is: RMB

### 1. Consolidated balance sheet

Preparation unit: Lepu Medical Technology (Beijing) Co., Ltd.

Unit: RMB

Item	30 June, 2023	1 January, 2023
Current assets:		
Monetary funds	4, 867, 489, 561. 07	5, 467, 278, 785. 39
Deposit reservation for balance		
Lending funds		
Trading financial assets	268, 578, 130. 94	277, 214, 058. 48
Derivative financial assets		
Notes receivable	83, 481, 118. 19	98, 366, 738. 81
Accounts receivable	1, 629, 129, 001. 51	1, 908, 630, 201. 32
Receivables financing	89, 814, 049. 18	134, 291, 997. 64
Advance payment	409, 245, 978. 49	381, 572, 138. 38
Premium receivable		
Reinsurance account receivable		
Provision of cession receivable		
Other receivables	151, 981, 381. 02	124, 645, 400. 43
Wherein: Interests receivable		
Dividends receivable		
Redemptory financial assets for purchase		
Inventories	2, 453, 277, 625. 13	2, 266, 591, 888. 06
Contract assets		
Held-for-sale assets		
Non-current assets due within one year	3, 769, 122. 82	4, 844, 368. 53
Other current assets	134, 104, 235. 38	85, 517, 197. 42
Total current assets	10, 090, 870, 203. 73	10, 748, 952, 774. 46
Non-current assets:		
Loan and advance payment issuance		
Creditors' investments		
Other creditors' investments		
Long-term receivables	5, 552, 391. 50	8, 259, 759. 08
Long-term equity investments	1, 204, 878, 773. 31	1, 229, 469, 446. 74
Other equity instrument investments	1, 181, 364, 625. 73	1, 168, 919, 655. 06
Other non-current financial assets	173, 680, 000. 00	158, 610, 000. 00
Investment real estate	308, 144, 319. 42	330, 246, 655. 45
Fixed assets	2, 630, 306, 513. 33	2, 604, 619, 204. 30

Engineering in progress	1, 664, 300, 415. 82	1, 513, 606, 170. 30
Productive biological assets		
Oil-gas assets		
Right-of-use assets	341, 115, 075. 75	221, 916, 109. 85
Intangible assets	1, 384, 435, 705. 74	1, 369, 652, 469. 86
Development expenditures	1, 113, 760, 957. 75	988, 319, 738. 44
Goodwill	3, 353, 428, 638. 30	3, 330, 976, 810. 89
Long-term unamortized expenses	228, 119, 327. 65	232, 882, 532. 36
Deferred income tax assets	141, 466, 806. 02	131, 471, 432. 98
Other non-current assets	618, 339, 481. 01	446, 130, 385. 24
Total non-current assets	14, 348, 893, 031. 33	13, 735, 080, 370. 55
Total assets	24, 439, 763, 235. 06	24, 484, 033, 145. 01
Current liabilities:		
Short-term loans	875, 323, 328. 96	380, 767, 436. 73
Borrowings from the central bank		
Borrowing funds		
Trading financial liabilities		
Derivative financial liabilities		
Notes payable	122, 283, 469. 67	182, 573, 344. 20
Accounts payable	968, 175, 591. 03	1, 337, 648, 654. 76
Advance receipt		
Contractual liabilities	285, 010, 621. 34	731, 115, 959. 06
Repurchase financial assets for sale		
Deposits from customers and interbank		
Acting trading securities		
Acting underwriting securities		
Employee remuneration payable	59, 675, 217. 53	206, 701, 431. 48
Taxes payable	133, 238, 585. 70	332, 693, 089. 65
Other payables	447, 123, 508. 22	481, 937, 974. 61
Wherein: Interests payable		
Dividends payable	8, 054, 343. 26	3, 353, 503. 56
Service charges and commissions payable		
Reinsurance account payable		
Held-for-sale liabilities		
Non-current liabilities due within one year	1, 082, 477, 578. 42	1, 560, 077, 144. 38
Other current liabilities	66, 779, 310. 67	109, 821, 099. 32
Total current liabilities	4, 040, 087, 211. 54	5, 323, 336, 134. 19
Non-current liabilities:		
Insurance contract reserves		
Long-term loans	1, 183, 741, 940. 91	731, 548, 392. 02

Bonds payables	1, 529, 576, 446. 33	1, 506, 513, 884. 78
Wherein: Preferred shares		
Perpetual bonds		
Lease liabilities	275, 995, 456. 69	162, 725, 224. 80
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred revenues	186, 033, 821. 74	183, 747, 808. 29
Deferred income tax liabilities	196, 686, 197. 99	205, 678, 436. 74
Other non-current liabilities		
Total non-current liabilities	3, 372, 033, 863. 66	2, 790, 213, 746. 63
Total liabilities	7, 412, 121, 075. 20	8, 113, 549, 880. 82
Owner's equities:		
Capital stock	1, 880, 610, 036. 00	1, 880, 609, 691. 00
Other equity instruments	214, 752, 228. 68	214, 753, 553. 08
Wherein: Preferred shares		
Perpetual bonds		
Capital reserves	3, 425, 608, 646. 87	3, 243, 079, 193. 31
Minus: Treasury shares	355, 820, 438. 37	355, 820, 438. 37
Other comprehensive revenues	-51, 560, 565. 75	-90, 764, 197. 71
Special reserves		
Surplus reserves	664, 046, 161. 45	664, 046, 161. 45
General risk reserves		
Undistributed profits	9, 943, 862, 747. 95	9, 590, 298, 798. 54
Total owners' equities attributable to the parent company	15, 721, 498, 816. 83	15, 146, 202, 761. 30
Minority shareholders' equity	1, 306, 143, 343. 03	1, 224, 280, 502. 89
Total owner's equities	17, 027, 642, 159. 86	16, 370, 483, 264. 19
Total liabilities and owner's equities	24, 439, 763, 235. 06	24, 484, 033, 145. 01

Legal representative: Pu Zhongjie    Chief Financial Officer: Wang Yong    Accounting Manager: Li Yun

## 2. Balance sheet of parent company

Unit: RMB

Item	30 June, 2023	1 January, 2023
Current assets:		
Monetary funds	2, 060, 642, 655. 26	2, 453, 996, 209. 68
Trading financial assets	12, 337, 168. 55	
Derivative financial assets		
Notes receivable		500, 000. 00
Accounts receivable	207, 152, 294. 66	190, 424, 139. 66
Receivables financing	2, 635, 649. 64	466, 906. 50
Advance payment	72, 571, 046. 79	75, 915, 731. 60
Other receivables	2, 109, 780, 591. 88	1, 738, 194, 238. 89
Wherein: Interests receivable		
Dividends receivable		

Inventories	299,470,673.32	268,471,006.13
Contract assets		
Held-for-sale assets		
Non-current assets due within one year		
Other current assets	323,719.76	1,332,439.64
Total current assets	4,764,913,799.86	4,729,300,672.10
Non-current assets:		
Creditors' investments		
Other creditors' investments		
Long-term receivables		
Long-term equity investments	9,729,361,951.47	9,415,081,474.03
Other equity instrument investments	795,310,557.28	761,235,737.08
Other non-current financial assets	173,680,000.00	158,610,000.00
Investment real estate	41,140,190.55	42,167,219.61
Fixed assets	347,519,966.40	354,883,224.71
Engineering in progress	9,693,645.57	12,861,392.97
Productive biological assets		
Oil-gas assets		
Right-of-use assets	7,230,888.78	9,919,402.63
Intangible assets	57,461,310.30	66,671,398.74
Development expenditures	278,923,228.14	232,640,379.55
Goodwill		
Long-term unamortized expenses	60,288,261.39	68,922,923.03
Deferred income tax assets	28,684,126.57	30,806,901.71
Other non-current assets	1,083,934,160.53	764,504,704.02
Total non-current assets	12,613,228,286.98	11,918,304,758.08
Total assets	17,378,142,086.84	16,647,605,430.18
Current liabilities:		
Short-term loans	475,375,916.67	150,143,041.70
Trading financial liabilities		
Derivative financial liabilities		
Notes payable		
Accounts payable	55,087,205.08	111,555,122.95
Advance receipt		
Contractual liabilities	17,092,419.44	52,735,425.78
Employee remuneration payable	7,877,482.42	34,106,247.66
Taxes payable	40,011,314.73	34,722,931.40
Other payables	2,559,236,179.62	1,933,265,762.01
Wherein: Interests payable		
Dividends payable	1,626,800.00	1,626,800.00
Held-for-sale liabilities		
Non-current liabilities due within one year	1,036,011,753.44	1,502,513,339.28

Other current liabilities	739,171.18	5,417,976.46
Total current liabilities	4,191,431,442.58	3,824,459,847.24
Non-current liabilities:		
Long-term loans	1,136,250,756.74	731,548,392.02
Bonds payables	1,529,576,446.33	1,506,513,884.78
Wherein: Preferred shares		
Perpetual bonds		
Lease liabilities	5,092,346.62	5,072,677.98
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred revenues	11,316,666.67	12,566,666.67
Deferred income tax liabilities		
Other non-current liabilities		
Total non-current liabilities	2,682,236,216.36	2,255,701,621.45
Total liabilities	6,873,667,658.94	6,080,161,468.69
Owner's equities:		
Capital stock	1,880,610,036.00	1,880,609,691.00
Other equity instruments	214,752,228.68	214,753,553.08
Wherein: Preferred shares		
Perpetual bonds		
Capital reserves	3,941,979,543.54	3,887,723,492.11
Minus: Treasury shares	355,820,438.37	355,820,438.37
Other comprehensive revenues	30,699,814.77	-3,824,056.34
Special reserves		
Surplus reserves	788,470,523.96	788,470,523.96
Undistributed profits	4,003,782,719.32	4,155,531,196.05
Total owner's equities	10,504,474,427.90	10,567,443,961.49
Total liabilities and owner's equities	17,378,142,086.84	16,647,605,430.18

Legal representative: Pu Zhongjie    Chief Financial Officer: Wang Yong    Accounting Manager: Li Yun

### 3. Consolidated profit statement

Unit: RMB

Item	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022
I. Gross operating revenues	4,301,457,705.65	5,333,506,938.54
Wherein: Operating revenues	4,301,457,705.65	5,333,506,938.54
Interest revenues		
Earned premiums		
Revenues of service charges and commissions		
II. Total operating costs	3,214,116,746.52	3,770,341,813.17
Wherein: Operating costs	1,509,970,638.81	2,021,400,250.06
Interest expenditures		
Expenditures of service		

charges and commissions		
Surrender value		
Net expenditure for insurance claims		
Accrual of net amount of reserve fund for insurance liabilities		
Policy dividend expenditures		
Reinsurance costs		
Taxes and surcharges	45,754,564.21	55,300,630.81
Sales expenses	803,746,164.81	822,978,485.39
Management expenses	377,645,539.43	365,121,198.11
R&D expenses	441,219,153.24	439,476,755.71
Financial expenses	35,780,686.02	66,064,493.09
Wherein: Interest expenses	86,972,386.71	100,007,986.27
Interest revenues	62,718,389.82	41,392,335.79
Plus: Other revenues	51,668,935.03	20,535,375.96
Investment revenues (the loss is expressed with "-")	-23,036,741.79	-39,941,078.60
Wherein: Revenues from investment in associated enterprises and joint ventures	-15,898,643.49	-43,519,739.55
Revenues from derecognition of financial assets measured by amortized cost		
Incomes from exchange (the loss is expressed with "-")		
Revenues from net exposure hedging (the loss is expressed with "-")		
Revenues from changes in fair value (the loss is expressed with "-")	16,271,677.41	-180,000.00
Losses from credit impairment (the loss is expressed with "-")	-17,866,091.94	-10,481,040.52
Losses from asset impairment (the loss is expressed with "-")	-1,938,876.67	-1,981,036.96
Revenues from assets disposal (the loss is expressed with "-")	1,253,000.35	367,424.89
III. Operating profits (the loss is expressed with "-")	1,113,692,861.52	1,531,484,770.14
Plus: Non-operating revenues	36,037,091.92	5,776,820.05
Minus: Non-operating expenditures	3,887,589.22	10,185,398.92
IV. Total profits (total loss is expressed with "-")	1,145,842,364.22	1,527,076,191.27
Minus: Income tax expenses	147,834,970.11	230,152,884.67
V. Net profits (the net loss is expressed with "-")	998,007,394.11	1,296,923,306.60
(I) Classification by operation continuity		
1. Net profits from continuing	998,007,394.11	1,296,923,306.60

operation (the net loss is expressed with "-")		
2. Net profits from discontinuing operation (the net loss is expressed with "-")		
(II) Classification by ownership		
1. Net profit attributable to the shareholders of parent company (the net loss is expressed with "-")	961,487,273.99	1,268,027,645.71
2. Minority shareholders' profit and loss (the net loss is expressed with "-")	36,520,120.12	28,895,660.89
VI. Net after-tax amount of other comprehensive incomes	54,203,488.44	-239,445,977.47
After-tax net amount of other comprehensive incomes attributable to the owners of the parent company	66,337,058.49	-232,377,565.68
(I) Other comprehensive incomes that cannot be reclassified into profits and losses	42,841,334.47	-253,942,316.31
1. Re-measurement of changed amount in the defined benefit plan		
2. Other comprehensive incomes that cannot be transferred into profits and losses under the equity method		
3. Fair value changes of other equity instrument investments	42,841,334.47	-253,942,316.31
4. Fair value changes of enterprise credit risk		
5. Others		
(II) Other comprehensive incomes that can be reclassified into profits and losses	23,495,724.02	21,564,750.63
1. Other comprehensive incomes that can be transferred into profits and losses under the equity method	88,434.75	18,282.44
2. Changes in fair value of other debt investments		
3. Amount of financial assets reclassified into other comprehensive incomes		
4. Credit impairment provision of other debt investments		
5. Cash flow hedging reserves		
6. Conversion difference in foreign currency financial statement	23,407,289.27	21,546,468.19
7. Others		
Net after-tax amount of other comprehensive revenues attributable to the minority shareholders	-12,133,570.05	-7,068,411.79
VII. Total comprehensive revenues	1,052,210,882.55	1,057,477,329.13
Total comprehensive revenues attributable to the owners of the parent company	1,027,824,332.48	1,035,650,080.03
Total comprehensive revenues amount attributable to minority shareholders	24,386,550.07	21,827,249.10
VIII. Incomes per share:		
(I) Basic earnings per share	0.5163	0.7117

(II) Diluted earnings per share	0.5147	0.7039
---------------------------------	--------	--------

As for the business merger under the same control in the current period, net profits achieved by the merged party before the merger is:0.00 RMB , and the net profit achieved by the combined party for the last period is:0.00 RMB.

Legal representative: Pu Zhongjie Chief Financial Officer: Wang Yong Accounting Manager: Li Yun

#### 4. Profit statement of the parent company

Unit: RMB

Item	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022
I. Operating revenues	803,122,402.96	767,194,609.99
Minus: Operating costs	259,554,620.22	255,502,690.32
Taxes and surcharges	11,712,690.39	11,057,402.86
Sales expenses	80,471,794.93	94,615,612.57
Management expenses	122,386,183.82	106,270,283.54
R&D expenses	78,161,750.21	83,046,734.41
R&D expenses	48,552,757.68	70,233,487.26
Wherein: Interest expenses	89,772,007.55	102,150,220.47
Interest revenues	55,047,329.81	32,741,950.08
Plus: Other revenues	3,444,826.30	6,234,129.79
Investment revenues (the loss is expressed with "-")	287,716,712.25	-39,232,623.78
Wherein: Revenues from investment in associated enterprises and joint ventures	-10,834,003.06	-42,303,476.62
Revenues from derecognition of financial assets measured by amortized cost		
Revenues from net exposure hedging (the loss is expressed with "-")		
Revenues from changes in fair value (the loss is expressed with "-")	15,609,168.55	-180,000.00
Losses from credit impairment (the loss is expressed with "-")	-1,197,097.30	5,807,516.34
Losses from asset impairment (the loss is expressed with "-")	-1,182,407.86	-1,505,465.52
Revenues from assets disposal (the loss is expressed with "-")		
III. Operating profits (the loss is expressed with "-")	506,673,807.65	117,591,955.86
Plus: Non-operating revenues	28,627.58	470,703.00
Minus: Non-operating expenditures	202,302.48	1,506,714.22
III. Total profits (total loss is expressed with "-")	506,500,132.75	116,555,944.64
Minus: Income tax expenses	23,191,858.37	17,401,062.69
IV. Net profits (the net loss is expressed with "-")	483,308,274.38	99,154,881.95
(I) Net profits from continuing	483,308,274.38	99,154,881.95

operation (the net loss is expressed with "-")		
(II) Net profits from discontinuing operation (the net loss is expressed with "-")		
V. Net after-tax amount of other comprehensive incomes	34,523,871.11	-32,729,216.85
(I) Other comprehensive incomes that cannot be reclassified into profits and losses	34,598,798.49	-32,747,499.29
1. Re-measurement of changed amount in the defined benefit plan		
2. Other comprehensive incomes that cannot be transferred into profits and losses under the equity method		
3. Fair value changes of other equity instrument investments	34,598,798.49	-32,747,499.29
4. Fair value changes of enterprise credit risk		
5. Others		
(II) Other comprehensive incomes that can be reclassified into profits and losses	-74,927.38	18,282.44
1. Other comprehensive incomes that can be transferred into profits and losses under the equity method	-74,927.38	18,282.44
2. Changes in fair value of other debt investments		
3. Amount of financial assets reclassified into other comprehensive incomes		
4. Credit impairment provision of other debt investments		
5. Cash flow hedging reserves		
6. Conversion difference in foreign currency financial statement		
7. Others		
VI. Total comprehensive revenues	517,832,145.49	66,425,665.10
VII. Incomes per share:		
(I) Basic earnings per share		
(II) Diluted earnings per share		

Legal representative: Pu Zhongjie    Chief Financial Officer: Wang Yong    Accounting Manager: Li Yun

## 5. Consolidated cash flow statement

Unit: RMB

Item	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022
I. Cash flows from operating activities:		
Cash received from the sales of goods or rendering of services	4,354,132,995.71	5,610,237,424.64
Net increase amount in customer deposits and interbank deposits		
Net increase amount in borrowings from the Central Bank		
Net increase amount in borrowing		

funds from other financial institutions		
Cash received from the original insurance contract premium		
Net amount of cash received from reinsurance premiums		
Net increase amount in insured deposit and investment		
Cash received for interests, service charges and commissions		
Net increase in borrowing funds		
Net increase amount in repurchase business funds		
Net cash amount received from vicariously traded securities		
Refund of tax and fees received	68,129,828.24	64,701,281.29
Other cash received related to operating activities	103,700,549.00	95,517,446.44
Subtotal of cash inflow from operating activities	4,525,963,372.95	5,770,456,152.37
Cash paid for goods purchased and labor services received	1,551,277,396.15	1,956,116,477.03
Net increase amount in customer loans and advances		
Net increase amount in deposit in the Central Bank and interbank payments		
Cash paid for the claim payment of the original insurance contract		
Net increase in lending funds		
Cash paid for interests, service charges and commissions		
Cash paid for policy dividends		
Cash paid to and for employees	1,247,456,846.24	1,097,096,898.30
Tax and fees paid	683,209,384.58	595,859,997.82
Other cash paid related to operating activities	902,318,152.80	943,089,801.48
Subtotal of cash outflow from operating activities	4,384,261,779.77	4,592,163,174.63
Net cash flow generated from operating activities	141,701,593.18	1,178,292,977.74
<b>II. Cash flows from investing activities:</b>		
Cash received from recouping investments	281,128,135.78	38,485,944.75
Cash received from investment incomes	35,630,696.93	5,984,489.37
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	6,049,538.67	1,193,256.00
Net cash received from disposal of subsidiaries and other business units		
Other cash received related to investing activities	2,694,175.14	26,512,304.82
Subtotal of cash inflow from investing activities	325,502,546.52	72,175,994.94

Net cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets	514,712,513.73	459,629,168.65
Cash paid for investments	321,752,357.06	211,409,126.64
Net increase in pledge loans		
Net cash paid for obtaining of subsidiaries and other business units	1,427,220.04	21,126,911.42
Other cash paid related to investing activities	90,875,108.80	127,327,936.94
Subtotal of cash outflow from investing activities	928,767,199.63	819,493,143.65
Net cash flow generated from investing activities	-603,264,653.11	-747,317,148.71
III. Cash flows from financing activities:		
Cash received from attracting investment	225,824,124.80	150,000.00
Wherein: Cash received from subsidiaries absorbing minority shareholders' investments	225,824,124.80	150,000.00
Cash received from obtaining borrowings	1,879,058,286.00	1,164,000,000.00
Other cash received related to financing activities	50,467,752.30	52,950,076.58
Subtotal of cash inflow from financing activities	2,155,350,163.10	1,217,100,076.58
Cash paid for the repayment of debts	1,382,625,000.00	1,115,635,360.00
Cash paid for the distribution of dividends, profits or repayment of interests	698,099,233.26	562,556,898.04
Wherein: Dividends and profits paid by subsidiaries to minority shareholders		1,937,837.84
Other cash paid related to financing activities	153,292,187.39	376,527,304.65
Subtotal of cash outflow from financing activities	2,234,016,420.65	2,054,719,562.69
Net cash flow generated from financing activities	-78,666,257.55	-837,619,486.11
IV. Effect of fluctuation in the exchange rate on cash and cash equivalents	-15,561,136.98	20,297,853.03
V. Net increase in cash and cash equivalents	-555,790,454.46	-386,345,804.05
Plus: Balance of cash and cash equivalents at the beginning of the period	5,309,297,789.78	3,684,043,645.03
VI. Balance of cash and cash equivalents at the end of the period	4,753,507,335.32	3,297,697,840.98

## 6. Cash flow statement of parent company

Unit: RMB

Item	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022
I. Cash flows from operating activities:		
Cash received from the sales of goods or rendering of services	873,065,670.15	838,092,067.14
Refund of tax and fees received	826,970.34	757,793.03
Other cash received related to	23,076,739.07	22,671,556.64

operating activities		
Subtotal of cash inflow from operating activities	896,969,379.56	861,521,416.81
Cash paid for goods purchased and labor services received	177,203,579.63	127,357,800.07
Cash paid to and for employees	306,400,575.73	278,012,538.49
Tax and fees paid	119,435,648.16	119,852,724.12
Other cash paid related to operating activities	118,598,770.61	122,762,896.10
Subtotal of cash outflow from operating activities	721,638,574.13	647,985,958.78
Net cash flow generated from operating activities	175,330,805.43	213,535,458.03
II. Cash flows from investing activities:		
Cash received from recouping investments	9,211,579.80	9,420,718.15
Cash received from investment incomes	308,720,000.00	26,730,804.52
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	3,546.50	30,703.77
Net cash received from disposal of subsidiaries and other business units		
Other cash received related to investing activities	672,896.66	15,032,220.83
Subtotal of cash inflow from investing activities	318,608,022.96	51,214,447.27
Net cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets	43,009,248.09	22,803,871.29
Cash paid for investments	75,404,319.21	152,611,914.00
Net cash paid for obtaining of subsidiaries and other business units	275,258,923.58	226,255,745.00
Other cash paid related to investing activities	48,250,000.00	64,800,000.00
Subtotal of cash outflow from investing activities	441,922,490.88	466,471,530.29
Net cash flow generated from investing activities	-123,314,467.92	-415,257,083.02
III. Cash flows from financing activities:		
Cash received from attracting investment		
Cash received from obtaining borrowings	1,470,000,000.00	1,080,000,000.00
Other cash received related to financing activities	49,267,707.71	813,657,517.29
Subtotal of cash inflow from financing activities	1,519,267,707.71	1,893,657,517.29
Cash paid for the repayment of debts	1,200,625,000.00	932,125,000.00
Cash paid for the distribution of dividends, profits or repayment of interests	702,991,984.55	558,932,797.84
Other cash paid related to financing activities	52,510,917.13	237,090,769.73
Subtotal of cash outflow from financing activities	1,956,127,901.68	1,728,148,567.57
Net cash flow generated from financing	-436,860,193.97	165,508,949.72

activities		
IV. Effect of fluctuation in the exchange rate on cash and cash equivalents	-18,085,169.36	-33,582.56
V. Net increase in cash and cash equivalents	-402,929,025.82	-36,246,257.83
Plus: Balance of cash and cash equivalents at the beginning of the period	2,451,299,231.74	1,001,034,621.83
VI. Balance of cash and cash equivalents at the end of the period	2,048,370,205.92	964,788,364.00

## 7. Consolidated Statement of Changes in Owners' Equities

Amount of the current period

Unit: RMB

Item	Six Months Ended June 30, 2023														
	Equity attributable to shareholders of the Company												Minority interests	Total equity	
	Share capital	Other equity instruments			Capital reserve	Less: Treasury shares	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risks	Retained earnings	Sub-total			Capital reserve
Preferece shares		Perpetual bonds	Others												
I. Year-ending balance of the previous year	1,880,609,691.00			214,753,553.08	3,243,079,193.31	355,820,438.37	-90,764,197.71		664,046,161.45		9,590,298,798.54		15,146,202,761.30	1,224,280,502.89	16,370,483,264.19
Plus: Changes in accounting policies															
Error correction in the previous period															
Business combination under the same control															
Others															
II. Beginning Balance of This Year	1,880,609,691.00			214,753,553.08	3,243,079,193.31	355,820,438.37	-90,764,197.71		664,046,161.45		9,590,298,798.54		15,146,202,761.30	1,224,280,502.89	16,370,483,264.19
III.	345			-	182		39,				353		575	81,	657

Increase/decrease in the current period (the decrease is expressed with "-")	.00			1,324.40	,529,453.56		203,631.96				,563,949.41		,296,055.53	862,840.14	,158,895.67
(I) Total comprehensive incomes							66,337,058.49				961,487,273.99		1,027,824,332.48	24,386,550.07	1,052,210,882.55
(II) Capital invested and reduced by the owners	345.00			-1,324.40	180,286,621.77								180,285,642.37	63,551,104.73	243,836,747.10
1. Ordinary shares invested by the owners															
2. Capital invested by other equity instrument holders	345.00			-1,324.40	10,120.40								9,141.00		9,141.00
3. Amount of share-based payment included into owners' equities					81,849,939.30								81,849,939.30	3,441,566.35	85,291,505.65
4. Others					98,426,562.07								98,426,562.07	60,109,538.38	158,536,100.45
(III) Profit distribution											-635,056,751.11		-635,056,751.11	-6,074,814.66	-641,131,565.77
1. Withdrawal of surplus reserves															
2. Withdraw of general risk reserves															
3. Distribution to owners (or shareholders)											-635,056,751.11		-635,056,751.11	-6,074,814.66	-641,131,565.77

											11		11		77
4. Others															
(IV) Internal carry-over of owners' equities											27,133,426.53				
1. Paid-in capital (or capital stock) transferred from capital reserves															
2. Transferring surplus public reserves into paid-in capital (or capital stock)															
3. Recovery of losses from surplus reserves															
4. Retained incomes of the changed amount carry-over in the defined benefit plan															
5. Retained earnings of the carry-over in other comprehensive incomes											27,133,426.53				
6. Others															
(V) Appropriative reserves															
1. Withdrawal in the current period															
2. Use in the current period															
(VI) Others					2,242,831.79								2,242,831.79		2,242,831.79

IV. Ending balance of the current period	1,880,610,036.00			214,752,228.68	3,425,608,647	355,820,438.37	-51,560,567.5		664,046,161.45		9,943,862,747.95		15,721,498,816.83	1,306,143,343.03	17,027,642,159.86
--	------------------	--	--	----------------	---------------	----------------	---------------	--	----------------	--	------------------	--	-------------------	------------------	-------------------

Amount of the previous year

Unit: RMB

Item	Six Months Ended June 30, 2023														
	Equity attributable to shareholders of the Company													Minority interests	Equity attributable to shareholders of the Company
	Share capital	Other equity instruments			Share capital	Other equity instruments	Share capital	Other equity instruments	Share capital	Other equity instruments	Share capital	Other equity instruments	Share capital		
		Preference shares	Perpetual bonds	Others											
I. Year-ending balance of the previous year	1,804,587,310.00			214,766,365.30	983,705,934.14	364,191,936.22	128,902,935.45		585,170,176.55		8,120,920,265.38		11,473,861,050.60	799,675,522.65	12,273,536,573.25
Plus: Changes in accounting policies															
Error correction in the previous period															
Business combination under the same control															
Others															
II. Beginning Balance of This Year	1,804,587,310.00			214,766,365.30	983,705,934.14	364,191,936.22	128,902,935.45		585,170,176.55		8,120,920,265.38		11,473,861,050.60	799,675,522.65	12,273,536,573.25
III. Increase/decrease in the	2,347.00			-9,078.32	120,903,578.32	235,644,141.32	-238,494,141.32				786,162,000.00		432,917,100.00	111,898,300.00	544,815,500.00

current period (the decrease is expressed with "-")				96	99.75	18.27	7,595.44				05.24		59.32	73.31	32.63
(I) Total comprehensive incomes							-232,377.565.68				1,268,027,645.71		1,035,650,080.03	21,827,249.10	1,057,477,329.13
(II) Capital invested and reduced by the owners	2,347.00			-9,078.96	32,200,078.21	235,644,18.27							-203,450,72.02	90,071,124.21	-113,379,647.81
1. Ordinary shares invested by the owners															
2. Capital invested by other equity instrument holders	2,347.00			-9,078.96	67,154.86								60,422.90		60,422.90
3. Amount of share-based payment included into owners' equities					33,710,840.41								33,710,840.41	2,780,594.30	36,491,434.71
4. Others					-1,577,917.06	235,644,18.27							-237,222,035.33	87,290,529.91	-149,931,505.42
(III) Profit distribution													-487,985,670.23	-487,985,670.23	-487,985,670.23
1. Withdrawal of surplus reserves															
2. Withdraw of general risk reserves															
3. Distribution to owners (or shareholders)													-487,985,670.23	-487,985,670.23	-487,985,670.23



IV. Ending balance of the current period	1,804,589,657.00			214,757,286.34	1,104,609,533.89	599,836,054.49	-109,594,659.99		585,170,176.55		8,907,082,270.62		11,906,778,209.92	911,573,895.96	12,818,352,105.88
--	------------------	--	--	----------------	------------------	----------------	-----------------	--	----------------	--	------------------	--	-------------------	----------------	-------------------

## 8. Statement of changes in the owners' equities of the parent company

Amount of the current period

Unit: RMB

Item	Six Months Ended June 30, 2023											
	Share capital	Other equity instruments			Capital reserve	Less: Treasury shares	Other comprehensive income	Special reserve	Surpluses reserve	Provision for general risks	Retained earnings	Sub-total
		Preference shares	Perpetual bonds	Others								
I. Year-ending balance of the previous year	1,880,609,691.00			214,753,553.08	3,887,723,492.11	355,820,438.37	-3,824,056.34		788,470,523.96	4,155,531,196.05		10,567,443,961.49
Plus: Changes in accounting policies												
Err or correction in the previous period												
Ot hers												
II. Beginning Balance of This Year	1,880,609,691.00			214,753,553.08	3,887,723,492.11	355,820,438.37	-3,824,056.34		788,470,523.96	4,155,531,196.05		10,567,443,961.49
III. Increase/decrease in the current period (the decrease is expressed with "-")	345.00			-1,324.40	54,256,051.43		34,523,871.11			-151,748,476.73		-62,969,533.59
(I) Total comprehensive incomes							34,523,871.11			483,308,274.38		517,832,145.49
(II) Capital invested and reduced by the owners	345.00			-1,324.40	52,044,661.42							52,043,682.02

1. Ordinary shares invested by the owners												
2. Capital invested by other equity instrument holders	345.00			-1,324.40	10,120.40							9,141.00
3. Amount of share-based payment included into owners' equities					56,016,623.99							56,016,623.99
4. Others					-3,982,082.97							-3,982,082.97
(III) Profit distribution									-635,056,751.11			-635,056,751.11
1. Withdrawal of surplus reserves												
2. Distribution to owners (or shareholders)									-635,056,751.11			-635,056,751.11
3. Others												
(IV) Internal carry-over of owners' equities												
1. Paid-in capital (or capital stock) transferred from capital reserves												
2. Transferring surplus public reserves into paid-in capital (or capital stock)												
3. Recovery of losses from surplus reserves												

4. Retained incomes of the changed amount carry-over in the defined benefit plan												
5. Retained earnings of the carry-over in other comprehensive incomes												
6. Others												
(V) Appropriative reserves												
1. Withdrawal in the current period												
2. Use in the current period												
(VI) Others					2,211,390.01							2,211,390.01
IV. Ending balance of the current period	1,880,610,036.00			214,752,228.68	3,941,979,543.54	355,820,438.37	30,699,814.77		788,470,523.96	4,003,782,719.32		10,504,474,427.90

Amount of the last period

Unit: RMB

Item	Six Months Ended June 30, 2022											
	Share capital	Other equity instruments			Capital reserve	Less: Treasury shares	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risks	Retained earnings	Sub-total
		Preference shares	Perpetual bonds	Others								
I. Year-ending balance of the previous year	1,804,587,310.00			214,766,365.30	2,561,836,944.62	364,191,936.22	65,171,925.73		709,594,539.06	3,931,015,798.72		8,922,780,947.21
Plus: Changes in accounting policies												
Err or correction in the												

previous period												
Others												
II. Beginning Balance of This Year	1,804,587,310.00			214,766,365.30	2,561,836,944.62	364,191,936.22	65,171,925.73		709,594,539.06	3,931,015,798.72		8,922,780,947.21
III. Increase/decrease in the current period (the decrease is expressed with "-")	2,347.00			-9,078.96	103,775,844.14	235,644,118.27	-38,849,246.61			-382,710,758.52		-553,435,011.22
(I) Total comprehensive incomes							-32,729,216.85			99,154,881.95		66,425,665.10
(II) Capital invested and reduced by the owners	2,347.00			-9,078.96	15,072,322.60	235,644,118.27						-220,578,527.63
1. Ordinary shares invested by the owners												
2. Capital invested by other equity instrument holders	2,347.00			-9,078.96	67,154.86							60,422.90
3. Amount of share-based payment included into owners' equities					15,005,167.74							15,005,167.74
4. Others						235,644,118.27						-235,644,118.27
(III) Profit distribution										-487,985,670.23		-487,985,670.23
1. Withdrawal of surplus reserves												
2. Distribution to owners (or shareholders)										-487,985,670.23		-487,985,670.23

3. Others												
(IV) Internal carry-over of owners' equities							- 6,120, 029. 76			6,120, 029. 76		
1. Paid-in capital (or capital stock) transferred from capital reserves												
2. Transferring surplus public reserves into paid-in capital (or capital stock)												
3. Recovery of losses from surplus reserves												
4. Retained incomes of the changed amount carry-over in the defined benefit plan												
5. Retained earnings of the carry-over in other comprehensive incomes							- 6,120, 029. 76			6,120, 029. 76		
6. Others												
(V) Appropriative reserves												
1. Withdrawal in the current period												
2. Use in the current period												
(VI) Others				88,70 3,521 .54								88,70 3,521 .54
IV. Ending balance of the current	1,804, 589, 657.0 0		214,7 57,28 6.34	2,665, 612, 788.7 6	599,8 36,05 4.49	26,32 2,679 .12		709,5 94,53 9.06	3,548, 305, 040.2 0		8,369, 345, 935.9 9	

period												
--------	--	--	--	--	--	--	--	--	--	--	--	--